Oral Lenacapavir (LEN) + F/TDF + Sub-cutaneous (SC) Lenacapavir (LEN) + Placebo SC LEN + PTM F/TDF + PTM Oral LEN + F/TAF (for US participants only)
Phase 3Active 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pre-Exposure Prophylaxis of HIV Infection
Conditions
Pre-Exposure Prophylaxis of HIV Infection
Trial Timeline
Jun 28, 2021 → Aug 1, 2028
NCT ID
NCT04925752About Oral Lenacapavir (LEN) + F/TDF + Sub-cutaneous (SC) Lenacapavir (LEN) + Placebo SC LEN + PTM F/TDF + PTM Oral LEN + F/TAF (for US participants only)
Oral Lenacapavir (LEN) + F/TDF + Sub-cutaneous (SC) Lenacapavir (LEN) + Placebo SC LEN + PTM F/TDF + PTM Oral LEN + F/TAF (for US participants only) is a phase 3 stage product being developed by Gilead Sciences for Pre-Exposure Prophylaxis of HIV Infection. The current trial status is active. This product is registered under clinical trial identifier NCT04925752. Target conditions include Pre-Exposure Prophylaxis of HIV Infection.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04925752 | Phase 3 | Active |
Competing Products
7 competing products in Pre-Exposure Prophylaxis of HIV Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Oral Lenacapavir (LEN) + Subcutaneous (SC) Lenacapavir (LEN) + F/TAF + F/TDF + Placebo SC LEN + PTM Oral LEN + PTM F/TAF + PTM F/TDF | Gilead Sciences | Phase 3 | 76 |
| Lenacapavir Tablet + Lenacapavir Injection + Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) | Gilead Sciences | Phase 2 | 51 |
| Lenacapavir Injection + Lenacapavir Tablet | Gilead Sciences | Phase 3 | 76 |
| Lenacapavir Injection + Lenacapavir Tablet + Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Gilead Sciences | Phase 2 | 51 |
| F/TAF + F/TDF + F/TAF Placebo + F/TDF Placebo | Gilead Sciences | Phase 3 | 76 |
| Lenacapavir Injection + Lenacapavir Tablet + Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Gilead Sciences | Phase 2 | 51 |
| Monoclonal antibody JST-010 + Placebo | Evotec | Phase 1 | 28 |